The present study aims to investigate the roles of nuclear-enriched abundant transcript 1 (NEAT1) in the regulation of oxaliplatin resistance to gastric cancer (GC). Oxaliplatin-resistant cell lines were constructed using stepwise selection. NEAT1 knockdown and overexpression of NEAT1 were performed. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and colony formation assays were used to evaluate cell proliferation. Propidium iodide (PI) and annexin V staining were used to evaluate cell apoptosis. A dual-luciferase reporter assay was used to evaluate the molecular interactions. Quantitative polymerase chain reaction (qPCR) was used to determine messenger RNA (mRNA) expression. Western blotting was used to determine the protein expression. Kaplan-Meier's analysis was performed to evaluate the relationship between NEAT1 and poor prognosis in GC. NEAT1 was upregulated in oxaliplatin-resistant GC cells and associated with poor prognosis in GC patients. NEAT1 knockdown suppressed oxaliplatin resistance, whereas overexpression of NEAT1 induced oxaliplatin resistance. In addition, the expressions of NEAT1 were negatively associated with miR-26 expressions. Overexpression of NEAT1 attenuated the inhibitory effects of miR-26 on the enhancer of zeste homolog 2 (EZH2). The roles of NEAT1 in the regulation of oxaliplatin resistance to GC are in part by ameliorating the inhibitory effect of miR-26 on EZH2.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cbin.11245 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study.
BMC Cancer
January 2025
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background: Colorectal cancer (CRC) is a common gastrointestinal cancer, and even though oxaliplatin chemotherapy is effective, there is a high likelihood of relapse, indicating the presence of oxaliplatin-resistant CRC. Therefore, it is crucial to comprehend the molecular mechanisms of oxaliplatin resistance and develop effective strategies to counter drug resistance. Numerous studies have demonstrated the close association between microRNAs (miRNAs) and drug resistance in CRC.
View Article and Find Full Text PDFPLGA-Nano-Encapsulated Disulfiram Inhibits Cancer Stem Cells and Targets Non-Small Cell Lung Cancer In Vitro and In Vivo.
Biomolecules
December 2024
Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Cancer stem cells (CSCs) play a key role in non-small cell lung cancer (NSCLC) chemoresistance and metastasis. In this study, we used two NSCLC cell lines to investigate the regulating effect of hypoxia in the induction and maintenance of CSC traits. Our study demonstrated hypoxia-induced stemness and chemoresistance at levels comparable to those in typical CSC sphere culture.
View Article and Find Full Text PDFCytotoxic activity of C polyacetylenes from the roots of Glehnia littoralis against drug-resistant colorectal and lung cancer cells.
J Nat Med
January 2025
College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.
Article Synopsis
- The study identified cytotoxic compounds, falcarinol and falcarindiol, from the roots of Glehnia littoralis, effective against both sensitive and resistant colorectal and lung cancer cells.
- Researchers isolated 13 polyacetylenes, including a new compound (3R,11R)-11-hyroxy-isofalcarinolone, using advanced chemical analysis techniques.
- Findings suggest that while these compounds show potential for anticancer development, their stability needs further investigation since some newly purified compounds did not exhibit expected activity.
Molecular Mechanisms of Synergistic Effect of PRIMA-1 and Oxaliplatin in Colorectal Cancer With Different p53 Status.
Cancer Med
January 2025
Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, People's Republic of China.
Article Synopsis
- The study investigates combining PRIMA-1 with oxaliplatin (L-OHP) to enhance treatment efficacy for colorectal cancer (CRC) while addressing the drug's toxicity and resistance issues.
- The results show that the combination therapy significantly improves cancer cell death and reduces cell migration and colony formation, regardless of p53 mutation status.
- RNA-seq analysis reveals different cellular responses to the treatments based on p53 status, and in vivo studies confirm that the combination therapy enhances effectiveness and reduces toxicity compared to PRIMA-1 alone.
Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis.
Fundam Clin Pharmacol
February 2025
Department Oncology Radiotherapy, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People Hospital, Zhejiang, China.
Background: The development of resistance to oxaliplatin is a multifaceted process, often involving modifications in drug transport, DNA repair mechanisms, and the ability of cells to evade drug-induced apoptosis.
Objective: To evaluate whether knocking down RFC3 promotes the sensitivity of colorectal cancer (CRC) cells to oxaliplatin, potentially offering a new approach to combat drug resistance.
Methods: siRNA-mediated knockdown of RFC3 was employed in colorectal cancer cell lines to assess the impact on oxaliplatin responsiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!